Amphastar Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Amphastar Pharmaceuticals, Inc. (AMPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $67.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-06
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $67.00K, a 97.71% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $1.72M, a 77.99% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $434.00K, a 88.23% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $370.00K, a 94.05% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $11.56M, a 77.80% decline from fiscal 2024.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $52.07M, a 74.04% increase from fiscal 2023.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $29.92M, a 40.60% increase from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $21.28M, a 169.15% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $67.00K 10-Q · filed 2026-08-06 | $1.79M 10-Q · filed 2026-08-06 | $2.23M derived: sum of 3 quarters · filed 2026-08-06 | $2.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.72M 10-Q · filed 2026-05-07 | $2.16M derived: sum of 2 quarters · filed 2026-05-07 | $2.53M derived: sum of 3 quarters · filed 2026-05-07 | $5.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $434.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $804.00K derived: sum of 2 quarters · filed 2026-02-26 | $3.73M derived: sum of 3 quarters · filed 2026-08-06 | $11.56M 10-K · filed 2026-02-26 |
| 2025-09-30 | $370.00K 10-Q · filed 2025-11-06 | $3.29M derived: sum of 2 quarters · filed 2026-08-06 | $11.13M 10-Q · filed 2025-11-06 | $14.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.92M 10-Q · filed 2026-08-06 | $10.76M 10-Q · filed 2026-08-06 | $14.44M derived: sum of 3 quarters · filed 2026-08-06 | $20.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $7.83M 10-Q · filed 2026-05-07 | $11.52M derived: sum of 2 quarters · filed 2026-05-07 | $17.74M derived: sum of 3 quarters · filed 2026-05-07 | $24.08M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.90M derived: sum of 2 quarters · filed 2026-02-26 | $16.25M derived: sum of 3 quarters · filed 2026-02-26 | $52.07M 10-K · filed 2026-02-26 |
| 2024-09-30 | $6.22M 10-Q · filed 2025-11-06 | $12.56M derived: sum of 2 quarters · filed 2025-11-06 | $48.38M 10-Q · filed 2025-11-06 | $53.76M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $6.34M 10-Q · filed 2025-08-07 | $42.16M 10-Q · filed 2025-08-07 | $47.54M derived: sum of 3 quarters · filed 2026-02-26 | $53.16M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $35.82M 10-Q · filed 2025-05-08 | $41.20M derived: sum of 2 quarters · filed 2026-02-26 | $46.83M derived: sum of 3 quarters · filed 2026-02-26 | $63.40M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $5.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.00M derived: sum of 2 quarters · filed 2026-02-26 | $27.58M derived: sum of 3 quarters · filed 2026-02-26 | $29.92M 10-K · filed 2026-02-26 |
| 2023-09-30 | $5.63M 10-Q · filed 2024-11-07 | $22.20M derived: sum of 2 quarters · filed 2024-11-07 | $24.54M 10-Q · filed 2024-11-07 | $25.69M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $16.57M 10-Q · filed 2024-08-09 | $18.92M 10-Q · filed 2024-08-09 | $20.06M derived: sum of 3 quarters · filed 2025-03-03 | $21.48M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $2.34M 10-Q · filed 2024-05-10 | $3.49M derived: sum of 2 quarters · filed 2025-03-03 | $4.91M derived: sum of 3 quarters · filed 2025-03-03 | $11.42M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $2.57M derived: sum of 2 quarters · filed 2025-03-03 | $9.08M derived: sum of 3 quarters · filed 2025-03-03 | $21.28M 10-K · filed 2025-03-03 |
| 2022-09-30 | $1.42M 10-Q · filed 2023-11-08 | $7.93M derived: sum of 2 quarters · filed 2023-11-08 | $20.13M 10-Q · filed 2023-11-08 | $22.75M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $6.51M 10-Q · filed 2023-08-09 | $18.71M 10-Q · filed 2023-08-09 | $21.32M derived: sum of 3 quarters · filed 2024-02-29 | $23.50M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $12.20M 10-Q · filed 2023-05-09 | $14.81M derived: sum of 2 quarters · filed 2024-02-29 | $16.99M derived: sum of 3 quarters · filed 2024-02-29 | $19.08M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $4.79M derived: sum of 2 quarters · filed 2024-02-29 | $6.88M derived: sum of 3 quarters · filed 2024-02-29 | $7.91M 10-K · filed 2024-02-29 |
| 2021-09-30 | $2.18M 10-Q · filed 2022-11-08 | $4.26M derived: sum of 2 quarters · filed 2022-11-08 | $5.29M 10-Q · filed 2022-11-08 | $5.80M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $2.09M 10-Q · filed 2022-08-09 | $3.12M 10-Q · filed 2022-08-09 | $3.62M derived: sum of 3 quarters · filed 2023-03-01 | $5.31M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $1.03M 10-Q · filed 2022-05-10 | $1.54M derived: sum of 2 quarters · filed 2023-03-01 | $3.22M derived: sum of 3 quarters · filed 2023-03-01 | $9.71M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $508.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $2.19M derived: sum of 2 quarters · filed 2023-03-01 | $8.68M derived: sum of 3 quarters · filed 2023-03-01 | $9.17M 10-K · filed 2023-03-01 |
| 2020-09-30 | $1.69M 10-Q · filed 2021-11-09 | $8.17M derived: sum of 2 quarters · filed 2021-11-09 | $8.66M 10-Q · filed 2021-11-09 | $8.86M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-06-30 | $6.49M 10-Q · filed 2021-08-09 | $6.97M 10-Q · filed 2021-08-09 | $7.17M derived: sum of 3 quarters · filed 2022-03-11 | $8.87M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-03-31 | $488.00K 10-Q · filed 2021-05-07 | $684.00K derived: sum of 2 quarters · filed 2022-03-11 | $2.38M derived: sum of 3 quarters · filed 2022-03-11 | $2.84M derived: sum of 4 quarters · filed 2022-03-11 |
| 2019-12-31 | $196.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $1.90M derived: sum of 2 quarters · filed 2022-03-11 | $2.35M derived: sum of 3 quarters · filed 2022-03-11 | $7.72M 10-K · filed 2022-03-11 |
| 2019-09-30 | $1.70M 10-Q · filed 2020-11-06 | $2.15M derived: sum of 2 quarters · filed 2020-11-06 | $7.52M 10-Q · filed 2020-11-06 | $11.25M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-06-30 | $452.00K 10-Q · filed 2020-08-07 | $5.82M 10-Q · filed 2020-08-07 | $9.55M derived: sum of 3 quarters · filed 2021-03-15 | $11.86M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-03-31 | $5.37M 10-Q · filed 2020-05-11 | $9.10M derived: sum of 2 quarters · filed 2021-03-15 | $11.40M derived: sum of 3 quarters · filed 2021-03-15 | $11.68M derived: sum of 4 quarters · filed 2021-03-15 |
| 2018-12-31 | $3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $6.03M derived: sum of 2 quarters · filed 2021-03-15 | $6.31M derived: sum of 3 quarters · filed 2021-03-15 | $7.37M 10-K · filed 2021-03-15 |
| 2018-09-30 | $2.30M 10-Q · filed 2019-11-08 | $2.58M derived: sum of 2 quarters · filed 2019-11-08 | $3.64M 10-Q · filed 2019-11-08 | $16.16M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $277.00K 10-Q · filed 2019-08-09 | $1.34M 10-Q · filed 2019-08-09 | $13.86M derived: sum of 3 quarters · filed 2020-03-16 | $15.52M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-03-31 | $1.06M 10-Q · filed 2019-05-10 | $13.58M derived: sum of 2 quarters · filed 2020-03-16 | $15.25M derived: sum of 3 quarters · filed 2020-03-16 | $18.28M derived: sum of 4 quarters · filed 2020-03-16 |
| 2017-12-31 | $12.52M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $14.19M derived: sum of 2 quarters · filed 2020-03-16 | $17.22M derived: sum of 3 quarters · filed 2020-03-16 | $17.25M 10-K · filed 2020-03-16 |
| 2017-09-30 | $1.67M 10-Q · filed 2018-11-09 | $4.71M derived: sum of 2 quarters · filed 2018-11-09 | $4.73M 10-Q · filed 2018-11-09 | $6.20M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-06-30 | $3.04M 10-Q · filed 2018-08-09 | $3.06M 10-Q · filed 2018-08-09 | $4.53M derived: sum of 3 quarters · filed 2019-03-15 | $9.53M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-03-31 | $24.00K 10-Q · filed 2018-05-10 | $1.49M derived: sum of 2 quarters · filed 2019-03-15 | $6.49M derived: sum of 3 quarters · filed 2019-03-15 | $7.46M derived: sum of 4 quarters · filed 2019-03-15 |
| 2016-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $6.46M derived: sum of 2 quarters · filed 2019-03-15 | $7.43M derived: sum of 3 quarters · filed 2019-03-15 | $7.45M 10-K · filed 2019-03-15 |
| 2016-09-30 | $5.00M 10-Q · filed 2017-11-09 | $5.96M derived: sum of 2 quarters · filed 2017-11-09 | $5.98M 10-Q · filed 2017-11-09 | $6.51M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | $967.00K 10-Q · filed 2017-08-09 | $982.00K 10-Q · filed 2017-08-09 | $1.51M derived: sum of 3 quarters · filed 2018-03-14 | $1.78M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | $15.00K 10-Q · filed 2017-05-10 | $541.00K derived: sum of 2 quarters · filed 2018-03-14 | $809.00K derived: sum of 3 quarters · filed 2018-03-14 | $3.07M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | $526.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $794.00K derived: sum of 2 quarters · filed 2018-03-14 | $3.06M derived: sum of 3 quarters · filed 2018-03-14 | $3.25M 10-K · filed 2018-03-14 |
| 2015-09-30 | $268.00K 10-Q · filed 2016-11-09 | $2.53M derived: sum of 2 quarters · filed 2016-11-09 | $2.72M 10-Q · filed 2016-11-09 | $2.72M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | $2.26M 10-Q · filed 2016-08-09 | $2.45M 10-Q · filed 2016-08-09 | $2.45M derived: sum of 3 quarters · filed 2017-03-15 | $2.74M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-03-31 | $189.00K 10-Q · filed 2016-05-10 | $189.00K derived: sum of 2 quarters · filed 2017-03-15 | $472.00K derived: sum of 3 quarters · filed 2017-03-15 | $333.00K derived: sum of 4 quarters · filed 2017-03-15 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $283.00K derived: sum of 2 quarters · filed 2017-03-15 | $144.00K derived: sum of 3 quarters · filed 2017-03-15 | $144.00K 10-K · filed 2017-03-15 |
| 2014-09-30 | $283.00K 10-Q · filed 2015-11-13 | $144.00K derived: sum of 2 quarters · filed 2015-11-13 | $144.00K 10-Q · filed 2015-11-13 | |
| 2014-06-30 | -$139.00K 10-Q · filed 2015-08-13 | -$139.00K 10-Q · filed 2015-08-13 | ||
| 2013-09-30 | $4.00K 10-Q · filed 2014-11-13 | $0.00 derived: sum of 2 quarters · filed 2014-11-13 | -$1.00K 10-Q · filed 2014-11-13 | |
| 2013-06-30 | -$4.00K 10-Q · filed 2014-08-13 | -$4.00K 10-Q · filed 2014-08-13 | ||
| 2012-12-31 | $1.55M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |